title: Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.
abstract: BACKGROUND
  Nonadherence in cancer patients taking oral anticancer drugs is common. Reasons for nonadherence are still not really understood as influencing factors are often complex, dynamic, and interrelated.
  
  
  OBJECTIVE
  A qualitative study was conducted to gain insight into (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors by exploring (1) processes and factors influencing (non-)adherence and (2) their interrelatedness.
  
  
  METHODS
  Semistructured interviews were held with 30 patients of different ages and with different types of cancer. A grounded theory approach was used.
  
  
  RESULTS
  Three foci were found when dealing with oral tyrosine kinase inhibitors: (1) a focus on survival, (2) a focus on quality of life, and (3) a balance between survival and quality of life. The process of adherence was determined by a set of complex and interrelated influencing factors: treatment-related side effects, hope, anxiety, trust, and feedback mechanisms.
  
  
  CONCLUSIONS
  This qualitative study gives insight into processes and factors influencing (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors. The results of this study can help healthcare professionals understand why patients taking oral tyrosine kinase inhibitors do not always adhere to their therapy.
  
  
  CONCLUSIONS
  Conditions should be created by which patients get maximum opportunity to establish a balance between survival and quality of life. An open climate and a trust-based relationship should be established in which patients feel comfortable to openly discuss their therapy and the difficulties they experience.
authors: Author Affiliations: University Centre for Nursing and Midwifery, Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, Ghent (Mr Verbrugghe, Ms Duprez, and Drs Beeckman, Grypdonck, Verhaeghe, and Van Hecke); Department of Hematology, University Hospital Ghent, Ghent (Marijke Quaghebeur); Department of Head and Neck Cancer, University Hospital Antwerp, Antwerp, Belgium (Dr Verschueren).
authors: Mathieu
authors: M
authors: Verbrugghe
authors: Veerle
authors: V
authors: Duprez
authors: Dimitri
authors: D
authors: Beeckman
authors: Mieke
authors: M
authors: Grypdonck
authors: Marijke
authors: M
authors: Quaghebeur
authors: Caroline
authors: C
authors: Verschueren
authors: Sofie
authors: S
authors: Verhaeghe
authors: Ann
authors: A
authors: Van Hecke
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D066296:Grounded Theory; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D036301:Qualitative Research; D011788:Quality of Life; D012307:Risk Factors; D016903:Drug Monitoring
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases